Japan, Brazil to cooperate in developing marine resources

BRASILIA, Brazil - Brazilian Foreign Minister Luiz Alberto Figueiredo (L) and Japanese Foreign Minister Fumio Kishida hold a press conference in Brasilia, Brazil, on Sept. 2, 2013, after their talks. They agreed to cooperate in developing marine resources, including underwater oilfields, off Brazil as well as satellite-oriented anti-disaster measures for the Latin American country.

Sample
PDF Preview

Product Code
ILEA001186656

Registered date
2013/9/03 00:00:00

Credit
Kyodo / Kyodo News Images

Media source
2013 Kyodo News

Media size
961 × 744 pixel

Resolution
240 dpi

Deployment size
114.97(KB)*

Special instruction

*File size when opened in Photoshop, etc.

Similar Images & Videos

Japan PM Kishida vows to downgrade COVID-19 categorization in spring

Japanese Prime Minister Fumio Kishida pledged Friday to downgrade the legal status of COVID-19 this spring to a Class 5 disease, the same level as seasonal influenza, a move that would lead to a major shift in the pandemic restrictions that have been in place for around three years. In Japan, COVID-19 is currently categorized as "equivalent to Class 2" and is subject to extensive steps, such as limitations on the movements of infected people and their close contacts. The measures are stricter than those against Class 2 infectious diseases, including tuberculosis and severe acute respiratory syndrome, or SARS.

Rocks hit climbers' backs in Mt. Ontake

NAGANO, Japan - Nagano Red Cross Hospital doctor Kaneyuki Furihata (L) and nurse Satoko Tokutake, who treated patients injured in the Mt. Ontake's eruption, speak at a press conference in Nagano City on Sept. 30, 2014. Furihata said rocks shot out of the volcano hit the victims from behind.

Japan Foreign Minister Kishida in Myanmar

NAYPYITAW, Myanmar - Japanese Foreign Minister Fumio Kishida (R) and Myanmar President Thein Sein shake hands before talking in Naypyitaw on March 24, 2014.

Tokyo governor resigns over money scandal

TOKYO, Japan - Tokyo Gov. Naoki Inose (L front) is pictured ahead of a press conference to announce his resignation over a money scandal at the metropolitan government offices on Dec. 19, 2013.

Myanmar's president in Japan

TOKYO, Japan - Myanmar's President Thein Sein (L side, front) and Japanese Prime Minister Shinzo Abe (R side, front) hold talks at Abe's office in Tokyo on Dec. 15, 2013.

Myanmar's president in Japan

TOKYO, Japan - Myanmar's President Thein Sein (L) and Japanese Prime Minister Shinzo Abe shake hands before holding talks at Abe's office in Tokyo on Dec. 15, 2013.

Amari to miss key TPP talks due to cancer treatment

TOKYO, Japan - Akira Amari, Japan's minister in charge of the Trans-Pacific Partnership free trade talks, announces at a press conference at the Cabinet Office in Tokyo on Dec. 5, 2013, that he will not be able to attend a TPP ministerial negotiating session starting Dec. 7 in Singapore, as he has been diagnosed with tongue cancer. Tokyo will send Amari's deputy, Yasutoshi Nishimura, senior vice minister of the Cabinet Office, instead to the four-day meeting.

Irish premier in Japan

TOKYO, Japan - Irish Prime Minister Enda Kenny (L) and Japanese Prime Minister Shinzo Abe shake hands before their talks in Tokyo on Dec. 2, 2013.

Online sales of over-the-counter drugs

TOKYO, Japan - Health, Labor and Welfare Minister Norihisa Tamura holds a press conference at the ministry in Tokyo on Nov. 6, 2013. The government said the same day that online sales of drugs moving from prescription to over-the-counter status will be banned for three years from the point of such movement in principle under new rules that could take effect next spring.

Novartis scandal

TOKYO, Japan - David Epstein (L), division head at Novartis AG, the Swiss-based pharmaceutical giant, speaks in a press conference in Tokyo on Oct. 3, 2013. At right is Yoshiyasu Ninomiya, president of Novartis Pharma K.K., a Japanese unit of Novartis AG. Novartis Pharma K.K. has allegedly engaged in deceptive advertizing for the blood pressure-lowering drug Diovan by citing a study based on manipulated clinical data.